Aptahem (APTA) Q1 2026 earnings summary

Executive summary

• Continued strategic focus on advancing the Apta-1 drug candidate, with strong industry interest and preparations for upcoming clinical phases and potential partnerships.

• Strategic collaboration with Hongene Biotech to optimize manufacturing costs, quality, and sustainability for Apta-1.

• Rights issue completed after the quarter, raising approximately 3.15 MSEK before costs to strengthen financial resilience and support business development.

Financial highlights

• Operating income for Q1 2026 was 574 KSEK, down from 642 KSEK in Q1 2025.

• Result after financial items improved to -1,392 KSEK from -2,018 KSEK year-over-year.

• Earnings per share were -0.07 SEK, compared to -0.16 SEK in the same quarter last year.

• Cash and cash equivalents at March 31, 2026, totaled 1,344 KSEK, up from 1,298 KSEK a year earlier.

Outlook and guidance

• Focus remains on cost-effective and value-creating development of Apta-1, with ongoing evaluation of strategic opportunities to maximize asset value.

• Management acknowledges a challenging financing climate for small biotech firms but notes increasing interest in differentiated, innovative projects.